- Dana-Farber researchers and colleagues completed a comprehensive genomic analysis of cervical cancer, identifying recurrent genetic mutations not previously found and shedding light on the role human papillomavirus (HPV) plays in the development of the disease.
Tags: BasicResearch, CervicalCancer, Genomics
- Dana-Farber/New Hampshire Oncology-Hematology (Dana-Farber/NHOH) held a reception to celebrate the five-year anniversary of the cancer center's founding in Londonderry, New Hampshire.
- Cancer death rates in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer, published online by the journal Cancer.
Tags: BreastCancer, ColonCancer, LungCancer, Prevention
- In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely.
Tags: chemotherapy, BreastCancer
- Women being treated with breast cancer drugs known as aromatase inhibitors can markedly ease the joint pain associated with the drugs by engaging in moderate daily exercise, Dana-Farber Cancer Institute and Yale University investigators report in a study to be presented during the San Antonio Breast Cancer Symposium.
Tags: BreastCancer, Exercise
- In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.
Tags: chemotherapy, BreastCancer, TargetedTherapy
- Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.
Tags: chemotherapy, ChildhoodCancer, Leukemia
- Dana-Farber researchers and their colleagues report a toxin linked to a targeted monoclonal antibody has shown antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment.
- Dana-Farber researchers found that adding bortezomib to initial treatment for chronic graft-versus-host disease allowed significant reduction of steroid medication in some patients.
Tags: GraftVersusHost, StemCellTransplant
- Dana-Farber researchers found an experimental drug blocked vulnerable cell growth pathways in a diverse group of aggressive B cell lymphomas, suggesting a potential new avenue for treating the most common type of non-Hodgkin lymphoma.
Showing 31-40 of 487 items